Standards for authorizing first-time trials of drugs in humans are lax, and should be strengthened in several ways, McGill University researchers argue in a paper published today in Nature.

Classified as: ethics, nature, drug, Clinical trials, first-in-human, preclinical, Kimmelman, Federico, STREAM
Published on: 30 Jan 2017
Back to top